Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 14, 2025

Trump's Fed pick comes into focus, economic data backlog clears: What to watch this week

View original at finance.yahoo.com
Trump's Fed pick comes into focus, economic data backlog clears: What to watch this week Stocks closed on Friday in the red, with the tech-heavy Nasdaq Composite (^IXIC) down roughly 1.7% while the blue-chip Dow Jones Industrial Average (^DJI) and benchmark S&P 500 (^GSPC) shed 0.5% and 1%, respectively…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The central question for Hassett nomination is whether Fed credibility will endure

    80% confidence

  • Kevin Hassett and Kevin Warsh are both great candidates for Fed chair

    80% confidence

  • Federal Reserve projects only one rate cut in 2026

    80% confidence

  • Debt issuance by hyperscalers represents a dramatic jump from pre-Covid levels

    80% confidence

  • Markets giving Hassett benefit of the doubt but perception that policy favors growth over price stability could risk unanchoring expectations

    80% confidence

  • There are a couple of other people besides Hassett and Warsh who are great Fed chair candidates

    80% confidence

  • There is a potential changing of the guard in the AI trade, with next big beneficiaries being businesses implementing the technology rather than chip manufacturers or hyperscalers

    80% confidence

  • USD weakening against other currencies is driven by news around the Fed's next leader

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Trump's Fed pick comes into focus, economic data backlog clears: What to watch this week — Source | Via News | ViaNews EU